eagle-i Global RepositoryGlobal Repository
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Clinical Proteomic Technologies for Cancer

eagle-i ID


Resource Type

  1. Government Agency


  1. Resource Description
    "To drive the development of a global resource of renewable affinity reagents (monoclonal antibodies) to cancer-associated targets for the research community, the National Cancer Institute (NCI) launched the Antibody Characterization Program. The goal of the program, which is part of the Office of Cancer Clinical Proteomics Research, is to facilitate the production, characterization and distribution of these valuable reagents to the global community in order to support protein/peptide measurement and analysis efforts. The Antibody Portal, serves as a gateway that provides visible access to a large number of reagents and accompanying characterization data to the research and industrial community. Antigens and antibodies are expressed, purified and characterized using standard operating procedures (SOPs), with all accompanying protocols and data made available to the public."
  2. Additional Name
  3. Affiliation
    National Cancer Institute
  4. Website(s)
Provenance Metadata About This Resource Record

Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016